Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Strata Critical MedicalSRTA +0.17%76 EV-to-EBITDA is -124.93 as of Aug. 13, 2026. GuruFocus rates SRTA with a GF Score™ of 76/100 and a GF Value™ of $4.73 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 513 Healthcare Providers & Services companies, Strata Critical Medical ranks worse than 194931.58% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Strata Critical Medical's enterprise value is $515.0 Mil.
Strata Critical Medical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-4.1 Mil. Therefore, Strata Critical Medical's EV-to-EBITDA for today is -124.93.
The historical rank and industry rank for Strata Critical Medical's EV-to-EBITDA or its related term are showing as below:
SRTA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -126 Med: -4.15 Max: -0.49
Current: -124.93
During the past 7 years, the highest EV-to-EBITDA of Strata Critical Medical was -0.49. The lowest was -126.00. And the median was -4.15.
SRTA's EV-to-EBITDA is ranked worse than 100% of 513
companies
in the Healthcare Providers & Services industry
Industry Median: 10.81
vs SRTA: -124.93
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Strata Critical Medical (NAS:SRTA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Strata Critical Medical's PE Ratio (TTM) for today is calculated as:
Strata Critical Medical's share price for today is $6.025.
Strata Critical Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.508.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Strata Critical Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strata Critical Medical EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Strata Critical Medical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Strata Critical Medical's EV-to-EBITDA falls into.
Strata Critical Medical's current Enterprise Value is $515.0 Mil.
Strata Critical Medical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strata Critical Medical (SRTA) has a EV-to-EBITDA of -124.93 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Strata Critical Medical. According to the industry distribution chart, Strata Critical Medical ranks #999999 out of 513 companies in the Healthcare Providers & Services industry.
Is Strata Critical Medical's EV-to-EBITDA too high?
Strata Critical Medical's current EV-to-EBITDA is -124.93. Based on the distribution chart, Strata Critical Medical ranks #999999 out of 513 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Strata Critical Medical has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strata Critical Medical's EV-to-EBITDA compare to CCRN and CYH?
According to the Healthcare Providers & Services industry distribution chart, Strata Critical Medical ranks #999999 out of 513 companies for EV-to-EBITDA. This places Strata Critical Medical in the lower half of its industry. The industry median EV-to-EBITDA is 10.81. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.81, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Strata Critical Medical. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strata Critical Medical's current EV-to-EBITDA is -124.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Critical Medical stock overvalued right now?
Based on GuruFocus' analysis, Strata Critical Medical (SRTA) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.73, compared to a current price of $6.03 — trading 27.4% above its estimated fair value. The current EV-to-EBITDA is -124.93. Strata Critical Medical's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Strata Critical Medical (SRTA), the current EV-to-EBITDA is -124.93 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strata Critical Medical (SRTA) Overvalued in 2026?
Based on GuruFocus' analysis, Strata Critical Medical stock appears to be overvalued.
The current stock price of $6.03 is trading 27.4% above its estimated GF Value™ of $4.73.
GuruFocus considers Strata Critical Medical to be Modestly Overvalued.
Key valuation signals for SRTA:
EV-to-EBITDA: -124.93
GF Value™: $4.73 vs. price of $6.03 (27.4% above fair value)
No single metric tells the full story. See the SRTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
76GF Score
Get the complete analysis for SRTA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRTA has been successfully added to your 
